Sanifit nets USD 80.9 M; FDA approves Dupixent for CRS; AbbVie buys Allergan

Sanifit raises USD 80.9 M to advance Calciphylaxis Pipeline

Sanifit, a clinical-stage biopharmaceutical company, has raised USD 80.9 million ( €72.2 million ) in total private fundraising. The financing mainly consisted led by Spain’s Caixa Capital Risc, along with many new investors, including Columbus Venture Partners and Alta Life Sciences. The proceeds raised will help Sanifit to advance further the clinical development of its lead candidate SNF472 for the treatment of calcific uremic arteriolopathy (CUA), also known as Calciphylaxis. Calciphylaxis therapeutic market is expected to change at a CAGR rate of 4.13% for the forecast period of 2019-28. The anticipated launch of Sodium thiosulfate (Hope Pharmaceuticals) and SNF472 (Sanifit), for the treatment of Calciphylaxis, is going to accelerate the Calciphylaxis market outlook.

First ever treatment for chronic rhinosinusitis with nasal polyps approved

The U.S. Food and Drug Administration today approved the combined drug of Regeneron and Sanofi, Dupixent (dupilumab), for the treatment of nasal polyps accompanied by chronic rhinosinusitis in adults. Chronic Rhinosinusitis (CRS), an inflammatory condition of the nose and sinuses, is a common medical condition that affects about 11% of adults in Europe and about 12% of adults in the United States. The Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) treatment options is limited. However, various other drugs, still not yet approved include omalizumab, and mepolizumab significantly reduces nasal polyp burden.

AbbVie acquires Allergan for USD 63 B

AbbVie is all set to acquire Irish Botox maker, Allergan for USD 63 Billion. The combined firm will comprise various franchises with positions across immunology, haematologic oncology, medical aesthetics, neuroscience, women’s health, eye care and virology. The acquisition will help Allergan to enhance its product portfolio- expected to grow at high-single-digit annual growth rate from more than $30 billion in 2020- a through AbbVie’s commercial strength, expertise and international infrastructure.